

company announcement

Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd, Denmark, 6 February 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons.

Please find below a statement of such trading in shares issued by Novo Nordisk.

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Liselotte Sofie Hyeved						
2	Reason for the notification							
a)	Position/status	Member of the Board of Directors						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>1,407 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	1,407 shares		
Price(s)	Volume(s)							
DKK 0.00	1,407 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	1,407 shares DKK 0.00						
e)	Date of the transaction	2025-02-05						
f)	Place of the transaction	Outside a trading venue						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Lars Fruergaard Jørgensen						
2	Reason for the notification							
a)	Position/status	President and CEO						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>98,702 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	98,702 shares		
Price(s)	Volume(s)							
DKK 0.00	98,702 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	98,702 shares DKK 0.00						
e)	Date of the transaction	2025-02-05						
f)	Place of the transaction	Outside a trading venue						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Lars Fruergaard Jørgensen						
2	Reason for the notification							
a)	Position/status	President and CEO						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Sale of shares						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>618.10 DKK</td> <td>32 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	618.10 DKK	32 shares		
Price(s)	Volume(s)							
618.10 DKK	32 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	32 shares 19,779 DKK						
e)	Date of the transaction	2025-02-05						
f)	Place of the transaction	AQUIS EXCHANGE EUROPE NON DISPLAY ORDER BOOK (NDOB)						

1 Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person Lars Fruergaard Jørgensen						
2 Reason for the notification							
a)	Position/status President and CEO						
b)	Initial notification/Amendment Initial notification						
3 Details of the issuer							
a)	Name Novo Nordisk A/S						
b)	LEI 549300DAQ1CVT6CXN342						
4 Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction Sale of shares						
c)	Price(s) and volume(s) <table border="1" data-bbox="863 1106 1362 1261"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>619.48 DKK</td> <td>1,104 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	619.48 DKK	1,104 shares		
Price(s)	Volume(s)						
619.48 DKK	1,104 shares						
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 1,104 shares 683,905 DKK						
e)	Date of the transaction 2025-02-05						
f)	Place of the transaction AQUIS EXCHANGE EUROPE						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Lars Fruergaard Jørgensen						
2	Reason for the notification							
a)	Position/status	President and CEO						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Sale of shares						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>617.56 DKK</td> <td>978 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	617.56 DKK	978 shares		
Price(s)	Volume(s)							
617.56 DKK	978 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	978 shares 603,976 DKK						
e)	Date of the transaction	2025-02-05						
f)	Place of the transaction	CBOE EUROPE - DXE PERIODIC (NL)						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Lars Fruergaard Jørgensen						
2	Reason for the notification							
a)	Position/status	President and CEO						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Sale of shares						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>621.01 DKK</td> <td>42 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	621.01 DKK	42 shares		
Price(s)	Volume(s)							
621.01 DKK	42 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	42 shares 26,083 DKK						
e)	Date of the transaction	2025-02-05						
f)	Place of the transaction	CBOE EUROPE - DXE DARK ORDER BOOK (NL)						

1 Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person Lars Fruergaard Jørgensen						
2 Reason for the notification							
a)	Position/status President and CEO						
b)	Initial notification/Amendment Initial notification						
3 Details of the issuer							
a)	Name Novo Nordisk A/S						
b)	LEI 549300DAQ1CVT6CXN342						
4 Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction Sale of shares						
c)	Price(s) and volume(s) <table border="1" data-bbox="865 1106 1362 1258"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>618.17 DKK</td> <td>8,331 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	618.17 DKK	8,331 shares		
Price(s)	Volume(s)						
618.17 DKK	8,331 shares						
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 8,331 shares 5,149,984 DKK						
e)	Date of the transaction 2025-02-05						
f)	Place of the transaction CBOE EUROPE - DXE ORDER BOOKS (NL)						

1 Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person Lars Fruergaard Jørgensen						
2 Reason for the notification							
a)	Position/status President and CEO						
b)	Initial notification/Amendment Initial notification						
3 Details of the issuer							
a)	Name Novo Nordisk A/S						
b)	LEI 549300DAQ1CVT6CXN342						
4 Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction Sale of shares						
c)	Price(s) and volume(s) <table border="1" data-bbox="865 1106 1362 1258"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>618.14 DKK</td> <td>1,577 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	618.14 DKK	1,577 shares		
Price(s)	Volume(s)						
618.14 DKK	1,577 shares						
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 1,577 shares 974,805 DKK						
e)	Date of the transaction 2025-02-05						
f)	Place of the transaction TURQUOISE EUROPE						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Lars Fruergaard Jørgensen						
2	Reason for the notification							
a)	Position/status	President and CEO						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Sale of shares						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>618.88 DKK</td> <td>22,936 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	618.88 DKK	22,936 shares		
Price(s)	Volume(s)							
618.88 DKK	22,936 shares							
d)	Aggregated information <ul style="list-style-type: none"> • Aggregated volume • Price 	22,936 shares 14,194,575 DKK						
e)	Date of the transaction	2025-02-05						
f)	Place of the transaction	NASDAQ COPENHAGEN A/S						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Maziar Mike Doustdar						
2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>36,956 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	36,956 shares		
Price(s)	Volume(s)							
DKK 0.00	36,956 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	36,956 shares DKK 0.00						
e)	Date of the transaction	2025-02-05						
f)	Place of the transaction	Outside a trading venue						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Maziar Mike Doustdar						
2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Sale of shares						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 614.55</td> <td>1,852 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 614.55	1,852 shares		
Price(s)	Volume(s)							
DKK 614.55	1,852 shares							
d)	Aggregated information <ul style="list-style-type: none"> • Aggregated volume • Price 	1,852 shares DKK 1,138,154						
e)	Date of the transaction	2025-02-05						
f)	Place of the transaction	Nasdaq Copenhagen						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Ludovic Helfgott						
2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>27,765 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	27,765 shares		
Price(s)	Volume(s)							
DKK 0.00	27,765 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	27,765 shares DKK 0.00						
e)	Date of the transaction	2025-02-05						
f)	Place of the transaction	Outside a trading venue						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Ludovic Helfgott						
2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Sale of shares						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 614.55</td> <td>8,990 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 614.55	8,990 shares		
Price(s)	Volume(s)							
DKK 614.55	8,990 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	8,990 shares DKK 5,524,840						
e)	Date of the transaction	2025-02-05						
f)	Place of the transaction	Nasdaq Copenhagen						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Ludovic Helfgott						
2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Sale of shares						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 617.00</td> <td>12,000 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 617.00	12,000 shares		
Price(s)	Volume(s)							
DKK 617.00	12,000 shares							
d)	Aggregated information <ul style="list-style-type: none"> • Aggregated volume • Price 	12,000 shares DKK 7,404,000						
e)	Date of the transaction	2025-02-06						
f)	Place of the transaction	Nasdaq Copenhagen						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Karsten Munk Knudsen						
2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>30,728 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	30,728 shares		
Price(s)	Volume(s)							
DKK 0.00	30,728 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	30,728 shares DKK 0.00						
e)	Date of the transaction	2025-02-05						
f)	Place of the transaction	Outside a trading venue						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Martin Holst Lange						
2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>30,728 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	30,728 shares		
Price(s)	Volume(s)							
DKK 0.00	30,728 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	30,728 shares DKK 0.00						
e)	Date of the transaction	2025-02-05						
f)	Place of the transaction	Outside a trading venue						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Tania Sabroe						
2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>10,561 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	10,561 shares		
Price(s)	Volume(s)							
DKK 0.00	10,561 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	10,561 shares DKK 0.00						
e)	Date of the transaction	2025-02-05						
f)	Place of the transaction	Outside a trading venue						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Marcus Schindler						
2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>30,728 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	30,728 shares		
Price(s)	Volume(s)							
DKK 0.00	30,728 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	30,728 shares DKK 0.00						
e)	Date of the transaction	2025-02-05						
f)	Place of the transaction	Outside a trading venue						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Camilla Sylvest						
2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>30,728 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	30,728 shares		
Price(s)	Volume(s)							
DKK 0.00	30,728 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	30,728 shares DKK 0.00						
e)	Date of the transaction	2025-02-05						
f)	Place of the transaction	Outside a trading venue						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Camilla Sylvest						
2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Sale of shares						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 615.00</td> <td>15,364 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 615.00	15,364 shares		
Price(s)	Volume(s)							
DKK 615.00	15,364 shares							
d)	Aggregated information <ul style="list-style-type: none"> • Aggregated volume • Price 	15.364 shares DKK 9,448,860						
e)	Date of the transaction	2025-02-05						
f)	Place of the transaction	Nasdaq Copenhagen						

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Henrik Ehlers Wulff						
2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333						
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>32,448 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	32,448 shares		
Price(s)	Volume(s)							
DKK 0.00	32,448 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	32,448 shares DKK 0.00						
e)	Date of the transaction	2025-02-05						
f)	Place of the transaction	Outside a trading venue						

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 72,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit [novonordisk.com](https://www.novonordisk.com), [Facebook](#), [Instagram](#), [X](#), [LinkedIn](#) and [YouTube](#).

Contacts for further information

Media:

Ambre James-Brown

+45 3079 9289

abmo@novonordisk.com

Liz Skrbkova (US)

+1 609 917 0632

lzsk@novonordisk.com

Investors:

Jacob Martin Wiborg Rode

+45 3075 5956

jrde@novonordisk.com

David Heiberg Landsted

+45 3077 6915

dhel@novonordisk.com

Sina Meyer

+45 3079 6656

azey@novonordisk.com

Ida Schaap Melvold

+45 3077 5649

idmg@novonordisk.com

Max Ung

+45 3077 6414

mxun@novonordisk.com

Frederik Taylor Pitter

+1 609 613 0568

fptr@novonordisk.com